MALVERN, Pa., June 28, 2024 /CNW/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") today announced that the Company has commenced trading on the OTCQX® Best Market ("OTCQX") under the ticker symbol NDOI.
"Trading on OTCQX is a clear signal that we are committed to life as a public company and providing shareholders with trading convenience as quickly as possible," said Blaise Coleman, Endo, Inc.'s President and Chief Executive Officer. "We remain focused on creating value for our shareholders as we execute on our strategic priorities through the development and delivery of life-enhancing therapies."
The OTCQX Market offers a valuable and convenient trading experience for U.S. investors, brokers and institutions. It is the premier market of OTC Markets Group, which is designed for established, investor-focused companies worldwide. Eligibility for trading on this platform requires companies to fulfill stringent financial and governance standards, adhere to U.S. securities laws, and maintain transparent and current disclosure.
Endo continues to work with the appropriate regulators, including the Securities and Exchange Commission, so that the Company's shares can begin trading on the New York Stock Exchange (NYSE) later in 2024, subject to required approvals and other customary conditions.
U.S. investors can find current financial disclosure and trading statistics, including Real-Time Level 2 quotes, for Endo on www.otcmarkets.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations of offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Endo
Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the statements by Mr. Coleman, any statements related to the listing, uplisting or trading of the Company's equity on OTCQX, NYSE or any other stock exchange, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws.
SOURCE Endo, Inc.
Media, Linda Huss, [email protected]; Investors, Laure Park, [email protected]
Share this article